Allogeneic hematopoietic stem cell transplantation for chronic myelomonocytic leukemia: a report of 12 patients / 中华血液学杂志
Chinese Journal of Hematology
;
(12): 113-116, 2013.
Article
in Chinese
| WPRIM
| ID: wpr-323432
ABSTRACT
<p><b>OBJECTIVE</b>To retrospectively review the efficacy of allogeneic hematopoietic stem cell transplantation (allo-HSCT) for chronic myelomonocytic leukemia (CMML).</p><p><b>METHODS</b>The engraftment, graft versus host disease (GVHD), infection, relapse and survival of 12 CMML patients received allo-HSCT were observed. The clinical outcome of allo-HSCT for CMML was analyzed.</p><p><b>RESULTS</b>Twelve (7 males and 5 females) CMML patients with a median age of 39 years old received allo-HSCT including 7 from HLA-matched sibling and 5 from haploidentical related donors. All 12 patients achieved engraftment. The median time of neutrophil engraftment and platelet engraftment were 15 (11 - 20) days and 13 (11 - 18) days, respectively. 4 patients occurred acute GVHD, and 3 occurred chronic GVHD. After the median follow-up of 17.5 months (12 - 32 months), the overall survival, disease free survival and relapse rate were 66.7%, 66.7%, and 16.7%, respectively.</p><p><b>CONCLUSION</b>Allo-HSCT can improve the survival of patients with CMML, and is a effective therapy for CMML.</p>
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Therapeutics
/
Transplantation, Homologous
/
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
/
Survival Rate
/
Retrospective Studies
/
Hematopoietic Stem Cell Transplantation
Type of study:
Observational study
Limits:
Adolescent
/
Adult
/
Child
/
Female
/
Humans
/
Male
Language:
Chinese
Journal:
Chinese Journal of Hematology
Year:
2013
Type:
Article
Similar
MEDLINE
...
LILACS
LIS